The DOI matches its Crossref record; 641 of the 641 references it cites were found in a registry or an index.
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Open accessAbstract
Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% of liver cancer cases and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) and C (HCV), and metabolic disorders. There are no obvious symptoms in the early stage of HCC, which often leads to delays in diagnosis. Therefore, HCC patients usually present with tumors in advanced and incurable stages. Several signaling pathways are dis-regulated in HCC and cause uncontrolled cell propagation, metastasis, and recurrence of HCC. Beyond the frequently altered and therapeutically targeted receptor tyrosine kinase (RTK) pathways in HCC, pathways involved in cell differentiation, telomere regulation, epigenetic modification and stress response also provide therapeutic potential. Investigating the key signaling pathways and their inhibitors is pivotal for achieving therapeutic advancements in the management of HCC. At present, the primary therapeutic approaches for advanced HCC are tyrosine kinase inhibitors (TKI), immune checkpoint inhibitors (ICI), and combination regimens. New trials are investigating combination therapies involving ICIs and TKIs or anti-VEGF (endothelial growth factor) therapies, as well as combinations of two immunotherapy regimens. The outcomes of these trials are expected to revolutionize HCC management across all stages. Here, we provide here a comprehensive review of cellular signaling pathways, their therapeutic potential, evidence derived from late-stage clinical trials in HCC and discuss the concepts underlying earlier clinical trials, biomarker identification, and the development of more effective therapeutics for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–600 of 641
Xu, Y., Chenna, V., Hu, C., Sun, H.-X., Khan, M. A., Bai, H., Yang, X., Zhu, Q., Sun, Y., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0950 · Cited by 79
Khan, M. W., Zhao, P., Asifullah, K., Raza, F., Raza, S. M., Sarfraz, M., Chen, Y., Li, M., Tan, Y., Ma, X., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s196651 · Cited by 79
Spahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B. P., Horger, M., Biskup, S., Feldhahn, M., Nahnsen, S., Hilke, F. J., et al. (2020) · Cancers · doi:10.3390/cancers12123830 · Cited by 79
Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia
Mangolini, M., Götte, F., Moore, A., Ammon, T., Oelsner, M., Lutzny‐Geier, G., Klein‐Hitpaß, L., Williamson, J. C., Lehner, P. J., Dürig, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06069-5 · Cited by 78
Dong, Z., Sun, D., Yang, Y., Zhou, W. J., Wu, R. T., Wang, X., Shi, K., Yan, Y., Yan, L., Yao, C., et al. (2019) · Hepatology · doi:10.1002/hep.31076 · Cited by 78
Schuchmann, M., Schulze‐Bergkamen, H., Fleischer, B., Schattenberg, J. M., Siebler, J., Weinmann, A., Teufel, A., Wörns, M., Fischer, T., Strand, S., et al. (2006) · Oncology Reports · doi:10.3892/or.15.1.227 · Cited by 77
The EGF receptor interacts with the type 1 IGF receptor and regulates its stability
Riedemann, J., Takiguchi, M., Sohail, M., & Macaulay, V. M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.012 · Cited by 77
Samarin, J., Laketa, V., Malz, M., Roessler, S. K., Stein, I., Horwitz, E. P., Singer, S., Dimou, E., Cigliano, A., Bissinger, M., et al. (2015) · Hepatology · doi:10.1002/hep.28357 · Cited by 77
Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Zhou, D., Luan, J., Huang, C., & Li, J. (2020) · Gut and Liver · doi:10.5009/gnl20223 · Cited by 77
Ponziani, F. R., De Luca, A., Picca, A., Marzetti, E., Petito, V., Del Chierico, F., Reddel, S., Paroni Sterbini, F., Sanguinetti, M., Putignani, L., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1905 · Cited by 77
Zhu, A. X., Ancukiewicz, M., Supko, J. G., Sahani, D. V., Blaszkowsky, L. S., Meyerhardt, J. A., Abrams, T. A., McCleary, N. J., Bhargava, P., Muzikansky, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3041 · Cited by 75
Cadoux, M., Caruso, S., Pham, S., Gougèlet, A., Pophillat, C., Riou, R., Loesch, R., Colnot, S., Nguyễn, C. T., Caldéraro, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.017 · Cited by 75
Liu, M., Zhang, L., Li, H., Hinoue, T., Zhou, W., Ohtani, H., El-Khoueiry, A. B., Daniels, J. R., O'Connell, C. L., Dorff, T. B., et al. (2018) · Hepatology · doi:10.1002/hep.30091 · Cited by 74
Villanueva, A., Toffanin, S., & Llovet, J. M. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328302c9e9 · Cited by 73
Garcia‐Vilas, J. A., & Medina, M. Á. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i33.3695 · Cited by 73
Zhu, M., Shi, X., Gong, Z., Su, Q., Yu, R., Wang, B., Yang, T., Dai, B., Zhan, Y., Zhang, D., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104868 · Cited by 73
Xiong, Y., Zhang, X., Zhu, J., Zhang, Y., Pan, Y., Wu, Y. Z., Zhao, J., Liu, J., Lu, Y., Liang, H., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01166-5 · Cited by 73
Liao, J., Xu, T., Zheng, J., Lin, J., Cai, Q., Yu, D., & Peng, J. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1358 · Cited by 72
Self-citationVarshney, A., Panda, J. J., Singh, A. K., Yadav, N., Bihari, C., Biswas, S., Sarin, S. K., & Chauhan, V. S. (2017) · Hepatology · doi:10.1002/hep.29643 · Cited by 72
Fazio, P. D., Schneider‐Stock, R., Neureiter, D., Okamoto, K., Wissniowski, T., Gahr, S., Quint, K., Meissnitzer, M. W., Alinger, B., Montalbano, R., et al. (2010) · Analytical Cellular Pathology · doi:10.1155/2010/847218 · Cited by 72
HBV integrations reshaping genomic structures promote hepatocellular carcinoma
Qian, Z., Liang, J., Huang, R., Song, W., Ying, J., Bi, X., Zhao, J., Shi, Z., Liu, W., Liu, J., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-330414 · Cited by 72
Ye, L., Mayerle, J. V., Ziesch, A., Reiter, F. P., Gerbes, A. L., & Toni, E. N. D. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0165-7 · Cited by 71
Ding, J., Li, H., Zhang, L., Zhou, Y., & Wu, J. H. (2021) · Cells · doi:10.3390/cells10010123 · Cited by 71
Zheng, J., Tan, Y., Liu, X., Zhang, C., Su, K., Jiang, Y. Z., Luo, J., Li, L., & Du, X. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-021-00899-5 · Cited by 71
Self-citationPD-1 coinhibitory signals: the link between pathogenesis and protection
Kulpa, D. A., Lawani, M., Cooper, A., Peretz, Y., Ahlers, J., & Sékaly, R.-P. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.02.002 · Cited by 70
A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma.
Lee, S. J., Lee, J., Sohn, I., Mao, M., Wang, K., Park, C.-K., & Lim, H. Y. (2013) · PubMed · Cited by 70
Lo, R. C., Leung, C. O. N., Chan, K. K., Ho, D. W., Wong, C., Lee, T. K., & Ng, I. O. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0059-x · Cited by 70
Self-citationLiu, Z.-K., Li, C., Zhang, R., Wei, D., Shang, Y., Yong, Y., Kong, L., Zheng, N.-S., Liu, K., Lu, M., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01377-9 · Cited by 70
Hedgehog Signaling Blockade Delays Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein
Arzumanyan, A. L., Sambandam, V., Clayton, M. M., Choi, S. S., Xie, G., Diehl, A. M., Yu, D., & Feitelson, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2329 · Cited by 69
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma
Panera, N., Crudele, A., Romito, I., Gnani, D., & Alisi, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010099 · Cited by 69
HGF/R-spondin1 rescues liver dysfunction through the induction of Lgr5+ liver stem cells
Yuan, L., Fang, Z., Liu, H., Wang, L., Cheng, Z., Tang, N., Li, T., Liu, T., Han, H.-X., Cao, G., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01341-6 · Cited by 69
Jensen, K. V., Cseh, O., Aman, A. M., Weiss, S., & Luchman, H. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189670 · Cited by 69
Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases
Heldin, C. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9484-2 · Cited by 68
Gnani, D., Romito, I., Artuso, S., Chierici, M., Stefanis, C. D., Panera, N., Crudele, A., Ceccarelli, S., Carcarino, E., Doria, V., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.34 · Cited by 68
Nam, S., Lee, A., Lim, J., & Lim, J.-S. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.201 · Cited by 68
Shiah, H.-S., Chen, C., Dai, C., Hsiao, C., Lin, Y., Su, W., Chang, J. ‐., Whang‐Peng, J., Lin, P. W., Huang, J., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12132 · Cited by 67
Okusaka, T., Ueno, H., Ikeda, M., Mitsunaga, S., Ozaka, M., Ishii, H., Yokosuka, O., Ooka, Y., Yoshimoto, R., Yanagihara, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12504 · Cited by 67
Rimassa, L., Abbadessa, G., Personeni, N., Porta, C., Borbath, I., Daniele, B., Salvagni, S., Laethem, J. V., Vlierberghe, H. V., Trojan, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11621 · Cited by 67
Aleksic, T., Gray, N., Wu, X., Rieunier, G., Osher, E. L., Mills, J. V., Verrill, C. L., Bryant, R. J., Han, C., Hutchinson, K., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3498 · Cited by 67
Mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) in carcinogenesis
Martin‐Kleiner, I., & Gall‐Tros̆elj, K. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.036 · Cited by 66
Pinato, D. J., Li, X., Mishra-Kalyani, P. S., D’Alessio, A., Fulgenzi, C. A. M., Scheiner, B., Pinter, M., Wei, G., Schneider, J., Rivera, D. R. R., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100747 · Cited by 66
Fujiwara, Y., Hoon, D. S. �., Yamada, T., Umeshita, K., Gotoh, M., Sakon, M., Nishisho, I., & Monden, M. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00943.x · Cited by 65
Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro
Wilson, G. S., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., & Qiao, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.009 · Cited by 65
Han, Z., Liu, S., Lin, H., Trivett, A. L., Hannifin, S., Yang, D., & Oppenheim, J. J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02338-4 · Cited by 65
Jeng, K., Jeng, C., Jeng, W., Sheen, I., Li, S., Leu, C., Tsay, Y., & Chang, C. (2019) · Oncology Letters · doi:10.3892/ol.2019.10826 · Cited by 65
Reidy‐Lagunes, D. L., Vakiani, E., Segal, M. F., Hollywood, E. M., Tang, L. H., Solit, D. B., Pietanza, M. C., Capanu, M., & Saltz, L. B. (2012) · Cancer · doi:10.1002/cncr.27459 · Cited by 64
The role of Hedgehog and Notch signaling pathway in cancer
Xia, R., Xu, M., Yang, J., & Ma, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00099-8 · Cited by 64
Fujii, T., Zen, Y., Harada, K., Niwa, H., Masuda, S., Kaizaki, Y., Watanabe, K., Kawashima, A., & Nakanuma, Y. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.12.010 · Cited by 63
Wei, T., Zhang, L., Lv, Y., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2537 · Cited by 63
Qu, W., Ding, Z., Qu, X.-D., Tang, Z., Zhu, G., Fu, X., Zhang, Z., Zhang, X., Huang, A., Tang, M., et al. (2022) · BJS Open · doi:10.1093/bjsopen/zrac114 · Cited by 63
Tai, W. M. D., Yong, W. P., Lim, C., Low, L., Tham, C. K., Koh, T. S., Ng, Q. S., Wang, W., Wang, L. Z., Hartano, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw415 · Cited by 62
NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma
Li, K., Zhu, X., Liu, H., Zhang, S.-Z., Li, X., Xiao, N., Liu, X., Xu, B., Lei, M., Zhang, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2549-2 · Cited by 62
Cui, G., Martin, R. C. G., Jin, H., Liu, X., Pandit, H., Zhao, H., Cai, L., Zhang, P., Li, W., & Li, Y. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0781-8 · Cited by 61
Self-citationEGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
He, X., Hikiba, Y., Suzuki, Y., Nakamori, Y., Kanemaru, Y., Sugimori, M., Sato, T. A., Nozaki, A., Chuma, M., & Maeda, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-12076-w · Cited by 61
Takeda, T., Komatsu, M., Chiwaki, F., Komatsuzaki, R., Nakamura, K., Tsuji, K., Kobayashi, Y., Tominaga, E., Ono, M., Banno, K., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2117-9 · Cited by 60
Puzanov, I. J., Sosman, J. A., Santoro, A., Saif, M. W., Goff, L. W., Dy, G. K., Zucali, P. A., Means-Powell, J. A., Ma, W. W., Simonelli, M., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0167-5 · Cited by 59
Lu, M., Fei, Z., & Zhang, G. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.006 · Cited by 59
Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma
Higashi, T., Hayashi, H., Kitano, Y., Yamamura, K., Kaida, T., Arima, K., Taki, K., Nakagawa, S., Okabe, H., Nitta, H., et al. (2016) · Medical Oncology · doi:10.1007/s12032-016-0845-6 · Cited by 58
Yang, S., Luo, C., Gu, Q., Xu, Q., Wang, G., Sun, H., Qian, Z., Tan, Y., Qin, Y., Shen, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6684 · Cited by 57
Goyal, L., Sirard, C. A., Schrag, M. L., Kagey, M. H., Eads, J. R., Stein, S., El-Khoueiry, A. B., Manji, G. A., Abrams, T. A., Khorana, A. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1310 · Cited by 57
Karabicici, M., Azbazdar, Y., Özhan, G., Şentürk, Ş., Karagonlar, Z. F., & Erdal, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.639779 · Cited by 57
Eckel, F., von Delius, S., Mayr, M. F., Dobritz, M., Fend, F., Hosius, C., Schleyer, E., Schulte‐Frohlinde, E., Schmid, R. M., & Lersch, C. (2005) · Oncology · doi:10.1159/000089990 · Cited by 56
Latasa, M. U., Salis, F., Urtasun, R., García‐Irigoyen, O., Elizalde, M., Uriarte, I., Santamaría, M., Feo, F., Pascale, R. M., Prìeto, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052711 · Cited by 55
Buontempo, F., Erşahin, T., Missiroli, S., Şentürk, Ş., Etro, D., Öztürk, M., Capitani, S., Çetin-Atalay, R., & Neri, L. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9486-3 · Cited by 55
Chen, J., Du, F., Dang, Y., Li, X., Qian, M., Feng, W., Qiao, C., Fan, D., Nie, Y., Wu, K., et al. (2019) · Hepatology · doi:10.1002/hep.30951 · Cited by 55
Self-citationSun, D., Liu, J., Wang, Y., & Dong, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.944537 · Cited by 55
Limousin, W., Laurent‐Puig, P., Ziol, M., Ganne‐Carrié, N., Nahon, P., Ait-Omar, A., Séror, O., Sidali, S., Campani, C., Blanc, P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.017 · Cited by 55
PTEN/MMAC1 Mutations in Hepatocellular Carcinomas: Somatic Inactivation of Both Alleles in Tumors
Kawamura, N., Nagai, H., Bando, K., Koyama, M., Matsumoto, S., Tajiri, T., Onda, M., Fujimoto, J., 植木, 孝., Konishi, N., et al. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00763.x · Cited by 54
Absence of epidermal growth factor receptor exon 18–21 mutation in hepatocellular carcinoma
Su, M.-C., Lien, H., & Jeng, Y. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.010 · Cited by 54
Tao, J., Krutsenko, Y., Moghe, A., Singh, S., Poddar, M., Bell, A., Oertel, M., Singhi, A. D., Geller, D., Chen, X., et al. (2021) · Hepatology · doi:10.1002/hep.31730 · Cited by 54
Kanzaki, H., Chiba, T., Ao, J., Koroki, K., Kanayama, K., Maruta, S., Maeda, T., Kusakabe, Y., Kobayashi, K., Kanogawa, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84117-9 · Cited by 54
Wang, Y., & Cao, K. (2021) · Journal of Immunology Research · doi:10.1155/2021/9965099 · Cited by 54
Yoo, C., Kang, J., Lim, H. Y., Kim, J. H., Lee, M. A., Lee, K.-H., Kim, T., & Ryoo, B. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.226 · Cited by 53
Bauer, T. M., Santoro, A., Lin, C., Garrido‐Laguna, I., Joerger, M., Greil, R., Spreafico, A., Yau, T. C. C., Goebeler, M.-E., Hütter‐Krönke, M. L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007353 · Cited by 53
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Pessino, G., Scotti, C., Maggi, M., & Immuno-Hub Consortium (2024) · Cancers · doi:10.3390/cancers16050901 · Cited by 53
Delgado, E. R., Okabe, H., Preziosi, M., Russell, J. O., Alvarado, T. F., Oertel, M., Nejak‐Bowen, K. N., Zhang, Y., & Monga, S. P. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.021 · Cited by 52
He, B., Dai, L., Zhang, X., Chen, D., Wu, J., Feng, X., Zhang, Y., Xie, H., Zhou, L., Wu, J., et al. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27661 · Cited by 52
Fang, S., Liu, M., Li, L., Zhang, F.-F., Li, Y., Yan, Q., Cui, Y.-Z., Zhu, Y.-H., Yuan, Y., & Guan, X. (2019) · Oncogene · doi:10.1038/s41388-019-0704-y · Cited by 52
Mei, Q., Chen, M., Lu, X.-C., Li, X., Duan, F., Wang, M., Luo, G., & Han, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3677 · Cited by 51
Tak, W. Y., Ryoo, B., Lim, H. Y., Kim, D. Y., Okusaka, T., Ikeda, M., Hidaka, H., Yeon, J.-E., Mizukoshi, E., Morimoto, M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0658-x · Cited by 51
Charette, N., Saeger, C. D., Lannoy, V., Horsmans, Y., Leclercq, I. A., & Stärkel, P. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-256 · Cited by 50
HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
Sueangoen, N., Tantiwetrueangdet, A., & Panvichian, R. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00407-1 · Cited by 50
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
Kusakabe, Y., Chiba, T., Oshima, M., Koide, S., Rizq, O., Aoyama, K., Ao, J., Kaneko, T., Kanzaki, H., Kanayama, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00889-0 · Cited by 50
TGF-β mediated drug resistance in solid cancer
Turati, M., Mousset, A., Issa, N., Turtoï, A., & Ronca, R. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.04.001 · Cited by 50
Down-regulation of Gli-1 inhibits hepatocellular carcinoma cell migration and invasion
Chen, J., Li, H.-S., Huang, J., Zhang, L., Chen, X., Wang, Q., Lei, J., Feng, J.-T., Liu, Q., & Huang, X. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2071-x · Cited by 49
Self-citationObora, A., Shiratori, Y., Okuno, M., Adachi, S., Takano, Y., Matsushima‐Nishiwaki, R., Yasuda, I., Yamada, Y., Akita, K., Sano, T., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.36369 · Cited by 49
Immune-Checkpoint Blockade Therapy in Lymphoma
Kuzume, A., Chi, S., Yamauchi, N., & Minami, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155456 · Cited by 49
Li, Y., Zhang, W., Doughtie, A., Cui, G., Li, X., Pandit, H., Yang, Y., Li, S., & Martin, R. C. G. (2016) · Oncotarget · doi:10.18632/oncotarget.10750 · Cited by 47
The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma
Chen, Z., Jiang, L., Liang, L., Koral, K., Zhang, Q., Zhao, L., Lu, S., & Tao, J. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.04.014 · Cited by 47
Zhou, Z., Li, X., Yang, G., Wang, J., Li, B., Huang, Y., Yan, J., & Tao, K. (2023) · Theranostics · doi:10.7150/thno.83377 · Cited by 47
Kang, G. H., Lee, B. S., Lee, E. S., Kim, S. H., Lee, H. Y., & Kang, D. Y. (2014) · Gut and Liver · doi:10.5009/gnl.2014.8.1.79 · Cited by 46
Lau, D. K., Tay, R. Y., Yeung, Y. H., Chionh, F. J. M., Mooi, J. K., Murone, C., Skrinos, E., Price, T. J., Mariadason, J. M., & Tebbutt, N. C. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0021-1 · Cited by 46
Zhou, Q., Jiang, H., Zhang, J., Yu, W., Zhou, Z., Huang, P., Wang, J., & Xiao, Z. (2018) · Cancer Management and Research · doi:10.2147/cmar.s182859 · Cited by 46
Liu, F., Wu, X., Qian, Y., Jiang, X. M., Wang, Y., & Gao, J. X. (2019) · Cell Death and Disease · doi:10.1038/s41419-020-2631-9 · Cited by 46
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes
Kwon, Y., Bose, S. K., Steele, R., Meyer, K., Bisceglie, A. M. D., Ray, R. B., & RAY, R. K. (2015) · Journal of Virology · doi:10.1128/jvi.01946-15 · Cited by 45
Sheng, X., Sun, X., Sun, K., Sui, H. X., Qin, J., & Li, Q. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3667 · Cited by 45
Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor
Ishii, Y., Hamashima, T., Yamamoto, S., & Sasahara, M. (2017) · Pathology International · doi:10.1111/pin.12530 · Cited by 45
The Wnt inhibitor LGK-974 enhances radiosensitivity of HepG2 cells by modulating Nrf2 signaling
Tian, D., Shi, Y., Chen, D., Liu, Q., & Fan, F. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4042 · Cited by 45
miR-515–5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway
Ni, J.-S., Zheng, H., Ou, Y.-L., Tao, Y., Wang, Z., Song, L., Yan, H.-L., & Zhou, W. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.03.003 · Cited by 45
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
Harding, J. J., Do, R. K., Yaqubie, A., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M. M. F., Benhadji, K. A., Kelley, R. K., & Abou‐Alfa, G. K. (2021) · Cancer Medicine · doi:10.1002/cam4.3880 · Cited by 45
Ryoo, B., Cheng, A., Ren, Z., Kim, T., Pan, H., Rau, K.-M., Choi, H. J., Park, J., Kim, J. H., Yen, C. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01380-3 · Cited by 45
Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma
Ding, S., Yang, Z., Wang, J., Zhang, X., Chen, X., & Lu, F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i20.6317 · Cited by 44
Delgado, E. R., Bahal, R., Yang, J., Lee, S. E., Ly, D. H., & Monga, S. P. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990081 · Cited by 44
Ou, D., Lee, B.-S., Lin, L., Liou, J., Liao, S., Hsu, C., & Cheng, A. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-2 · Cited by 44
Namoto, K., Baader, C., Orsini, V., Landshammer, A., Breuer, E., Dinh, K. T., Ungricht, R., Pikiolek, M., Laurent, S., Lu, B., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.03.003 · Cited by 44
Synergism in actions of HBV with aflatoxin in cancer development
Jin, J., Kouznetsova, V. L., Kesari, S., & Tsigelny, I. F. (2023) · Toxicology · doi:10.1016/j.tox.2023.153652 · Cited by 43
The histone acetyltransferase hMOF suppresses hepatocellular carcinoma growth
Zhang, J., Liu, H., Pān, H., Yang, Y., Huang, G., Yang, Y., Zhou, W., & Pan, Z. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.122 · Cited by 42
Chun, Y., Huang, M., Rink, L. A., & von Mehren, M. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-231 · Cited by 42
Zhao, Z., Song, J., Zhang, D., Wu, F., Tu, J., & Ji, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118642 · Cited by 42
Xiao, L., Liu, W., Geng, C., Li, T., Li, Y., Guo, Y., & Wang, C. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500129 · Cited by 42
Shi, M., Wang, W., Zhang, J., Li, B., Lv, D., Wang, D., Wang, S., Cheng, D., & Ma, T. (2021) · Cancer Science · doi:10.1111/cas.15181 · Cited by 42
Self-citationHeo, J., Liang, J., Kim, C. W., Woo, H. Y., Shih, I., Su, T., Lin, Z., Yoo, S. Y., Chang, S., Urata, Y., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.006 · Cited by 42
Chen, S., Han, P., Zhang, Q., Liu, P., Liu, J., Zhao, L., Guo, L., & Li, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1179014 · Cited by 42
Fu, M., Shi, W., Li, Z., & Liu, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.147 · Cited by 41
Song, L., Luo, Y., Li, S., Hong, M., Wang, Q., Chi, X., & Yang, C. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s270124 · Cited by 41
Song, J., Eum, D., Park, S.-Y., Jin, Y., Shim, J.-W., Park, S.-J., Kim, M., Park, S.-J., Heo, K., & Choi, Y.-J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240533 · Cited by 41
Park, D.-J., Sung, P. S., Lee, G.-W., Cho, S., Kim, S., Kang, B.-Y., Hur, W., Yang, H., Lee, S. K., Lee, S. H., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094710 · Cited by 41
Roy, A. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.07.003 · Cited by 41
Paur, J., Nika, L., Maier, C., Moscu‐Gregor, A., Kostka, J., Huber, D., Mohr, T. T., Heffeter, P., Schrottmaier, W. C., Kappel, S., et al. (2015) · Hepatology · doi:10.1002/hep.28023 · Cited by 40
Kang, M. S., Baek, S., Chun, Y. S., Moore, A. Z., Landman, N., Berman, D. E., Yang, H. O., Morishima‐Kawashima, M., Osawa, S., Funamoto, S., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445734 · Cited by 40
Razumilava, N., & Gores, G. J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.01.017 · Cited by 40
Ou, D., Shen, Y., Liang, J., Liou, J., Yu, S., Fan, H., Wang, D.-S., Lu, Y., Hsu, C., & Cheng, A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3294 · Cited by 40
A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer
Muñoz-Rojas, A. R., Zhang, P., Wang, Y., Foo, W. C., Muñoz, N. M., Xiao, L., Wang, J., Gores, G. J., Hung, M., & Blechacz, B. R. A. (2016) · Neoplasia · doi:10.1016/j.neo.2016.04.002 · Cited by 40
A Novel Indolizine Derivative Induces Apoptosis Through the Mitochondria p53 Pathway in HepG2 Cells
Liu, Y., Shao, E., Zhang, Z., Yang, D., Li, G., Cao, H., & Huang, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00762 · Cited by 40
Hisada, R., Yoshida, N., Umeda, M., Burbano, C., Bhargava, R., Scherlinger, M., Kono, M., Kyttaris, V. C., Krishfield, S., & Tsokos, G. C. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00874-1 · Cited by 40
The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma
Poté, N., Cros, J. F., Laouirem, S., Raffenne, J., Negrão, M., Albuquerque, M., Bédossa, P., Ferreira, M. G., Ait‐Si‐Ali, S., Fior, R., et al. (2020) · Liver International · doi:10.1111/liv.14381 · Cited by 39
Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance
Feng, M., Santhanam, R. K., Xing, H., Zhou, M.-S., & Jia, H. M. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115991 · Cited by 39
Chatzipanagiotou, O. P., Loukas, C., Vailas, M. G., Machairas, N., Kykalos, S., Charalampopoulos, G., Filippiadis, D. K., Felekouras, E., & Schizas, D. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16663 · Cited by 39
Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma
Zhou, X., Ding, J., Li, H., Zuo, J., Ge, S., Jia, H., & Wu, J. H. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15090 · Cited by 38
Harada, K., Ohashi, R., Naito, K., & Kanki, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093126 · Cited by 38
Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans
Zhang, S., Wang, J., Wang, H., Fan, L., Fan, B., Zeng, B., Tao, J., Li, X., Che, L., Cigliano, A., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.12.017 · Cited by 37
Decaens, T., Barone, C., Assénat, E., Wermke, M., Fasolo, A., Merle, P., Blanc, J., Grando, V., Iacobellis, A., Villa, E., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01334-9 · Cited by 37
Liu, Z., Chen, D., Ning, F., Du, J., & Wang, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26625 · Cited by 36
Potentiating cancer vaccine efficacy in liver cancer
Tagliamonte, M., Petrizzo, A., Mauriello, A., Tornesello, M. L., Buonaguro, F. M., & Buonaguro, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1488564 · Cited by 36
Li, H., Zhang, B., Ding, M., Lu, S., Zhou, H., Sun, D., Wu, G., & Gan, X. (2019) · Hepatology International · doi:10.1007/s12072-019-09944-5 · Cited by 36
Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
Yang, X., Zhu, L.-C., Wang, Y., Li, Y., & Wang, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00887 · Cited by 35
Khan, M. G. M., Ghosh, A., Variya, B. C., Santharam, M. A., Ihsan, A. U., Ramanathan, S., & Ilangumaran, S. (2020) · BMC Cancer · doi:10.1186/s12885-020-07285-3 · Cited by 35
Yu, J. J., Chen, G. G., & Lai, P. B. S. (2020) · Medicinal Research Reviews · doi:10.1002/med.21738 · Cited by 35
Xie, Q. R., Guo, H., He, P., Deng, H., Gao, Y., Dong, N., Niu, W., Liu, T., Li, M., Wang, S., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12980 · Cited by 35
Self-citationRecent updates on Wnt signaling modulators: a patent review (2014-2020)
Goswami, V., & Patel, B. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1940138 · Cited by 35
Gomes, S., Bosco, B., Loureiro, J. B., Ramos, H., Raimundo, L., Soares, J., Nazareth, N., Barcherini, V., Domingues, L., Oliveira, C., et al. (2019) · Cancers · doi:10.3390/cancers11081151 · Cited by 34
C-Kit, a Double-Edged Sword in Liver Regeneration and Diseases
Wang, W., Shui, L., Liu, Y., & Zheng, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.598855 · Cited by 34
Wang, H., Yang, J., Zhang, K., Liu, J., Li, Y., Su, W., & Song, N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.650388 · Cited by 34
Shimose, S., Hiraoka, A., Gardini, A. C., Tsutsumi, T., Nakano, D., Iwamoto, H., Tada, F., Rimini, M., Tanaka, M., Torimura, T., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13843 · Cited by 34
Zhu, A. X., Kang, Y., Rosmorduc, O., Evans, T. R. J., Santoro, A., Ross, P. J., Gane, E. J., Vogel, A., Jeffers, M., Meinhardt, G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2883 · Cited by 33
Kotiyal, S., & Evason, K. J. (2021) · Cancers · doi:10.3390/cancers13164202 · Cited by 33
Hennig, M., Yip-Schneider, M., Wentz, S. C., Wu, H., Hekmatyar, S. K., Klein, P., Bansal, N., & Schmidt, C. M. (2009) · Hepatology · doi:10.1002/hep.23470 · Cited by 32
Liu, W., Tang, Q., Zhang, Q., Hu, C., Huang, J., Sheng, F., Liu, Y., Zhou, M., Lai, W., Li, G., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00651 · Cited by 32
Song, S., Yu, Z., You, Y., Liu, C., Xie, X., Lv, H., Xiao, F., Zhu, Q., & Qin, C. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04796-8 · Cited by 32
Liang, B.-Y., Wang, H., Qiao, Y., Wang, X., Qian, M., Song, X., Zhou, Y., Zhang, Y., Shang, R., Che, L., et al. (2022) · Hepatology · doi:10.1002/hep.32693 · Cited by 32
Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression
Midorikawa, Y., Yamamoto, S., Tatsuno, K., Renard-Guillet, C., Tsuji, S., Hayashi, A., Ueda, H., Fukuda, S., Fujita, T., Katoh, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0225 · Cited by 31
Huynh, H. T., Prawira, A., Le, T. B. U., Vu, T. C., Hao, H.-X., Huang, A., Wang, Y., & Porta, D. G. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00524-4 · Cited by 31
Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence
Zhang, S., Lin, T., Xiong, X., Chen, C., Tan, P., & Wei, Q. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00857-z · Cited by 31
Tahtouh, R., Azzi, A., Alaaeddine, N., Chamat, S., Bouharoun‐Tayoun, H., Wardi, L., RAAD, I. I., Sarkis, R., Antoun, N. A., & Hilal, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119512 · Cited by 30
Ang, C., Miura, J. T., Gamblin, T. C., He, R., Xiu, J., Millis, S. Z., Gatalica, Z., Reddy, S. K., Yee, N. S., & Abou‐Alfa, G. K. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.24086 · Cited by 30
Interacting network of Hippo, Wnt/β-catenin and Notch signaling represses liver tumor formation
Kim, W., Khan, S. K., & Yang, Y. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.1.196 · Cited by 30
Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole
Li, K., Fang, D., Xiong, Z., & Luo, R. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s223119 · Cited by 30
HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice
Afaloniati, H., Angelopoulou, K., Giakoustidis, A. E., Hardas, A., Pseftogas, A., Makedou, K., Gargavanis, A. A., Goulopoulos, T., Iliadis, S., Papadopoulos, V. N., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s250233 · Cited by 30
Lim, M., Franses, J. W., Imperial, R. J. L., Majeed, U., Tsai, J., & Hsiehchen, D. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.023 · Cited by 29
Song, L. J., Guo, L., & Li, Z. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.03.003 · Cited by 28
Yang, Y., Deng, Y., Chen, X., Zhang, J., Chen, Y., Li, H., Wu, Q., Yang, Z., Zhang, L., & Liu, B. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.05.033 · Cited by 28
Qiu, Z., Zhang, C., Zhou, J., Hu, J., Sheng, L., Li, X., Chen, L., Li, X., Deng, X., & Zheng, G. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22904 · Cited by 28
Pallozzi, M., Tommaso, N. D., Maccauro, V., Santopaolo, F., Gasbarrini, A., Ponziani, F. R., & Pompili, M. (2022) · Cancers · doi:10.3390/cancers14194631 · Cited by 28
Lu, Y., Chia-Hung, C., Tzen, K., Gao, M., Cheng, A., Kulp, S. K., & Cheng, J. C. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.12.022 · Cited by 27
Meng (2010) · Oncology Reports · doi:10.3892/or_00000960 · Cited by 27
Shi, X.-D., Yu, X., Wu, W., Xu, X., Wang, J., Xu, L., Zhang, R., & Liu, C. (2016) · Oncotarget · doi:10.18632/oncotarget.11859 · Cited by 27
Xu, G., Zhu, L., Wang, Y., Shi, Y., Gong, A., & Wu, C. (2017) · BioMed Research International · doi:10.1155/2017/1832494 · Cited by 27
Yen, C.-J., Kim, T., Feng, Y., Chao, Y., Lin, D., Ryoo, B., Huang, D., Schnell, D., Hocke, J., Loembé, A., et al. (2018) · Liver Cancer · doi:10.1159/000486460 · Cited by 27
Al‐Fayoumi, S., Hashiguchi, T., Shirakata, Y., Mascarenhas, J. O., & Singer, J. W. (2018) · Journal of Experimental Pharmacology · doi:10.2147/jep.s150729 · Cited by 27
Zhan, N., Michael, A. A., Wu, K., Zeng, G., Bell, A. W., Tao, J., & Monga, S. P. (2018) · Gene Expression · doi:10.3727/105221618x15174108894682 · Cited by 27
Liu, C., Miao, X., Wang, Y., Wen, L., Cheng, X., Kong, D., Zhao, P., Song, D., Wang, X., Ding, X., et al. (2020) · Cancer Science · doi:10.1111/cas.14588 · Cited by 27
Das, B. K. (2022) · Apmis · doi:10.1111/apm.13282 · Cited by 27
Zhou, C., Yang, Z., Sun, B., Yi, Y., Wang, Z., Zhou, J., Fan, J., Gan, W., Ren, N., & Qiu, S. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s401639 · Cited by 27
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights
Abdellateif, M. S., Bayoumi, A., & Mohammed, M. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s404648 · Cited by 27
Chen, M.-C., Huang, H.-H., Lai, C.-Y., Lin, Y.-J., Liou, J., Lai, M.-J., Li, Y., Teng, C., & Yang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.6352 · Cited by 26
Qiao, Y., Xu, M. M., Tao, J., Che, L., Cigliano, A., Monga, S. P., Calvisi, D. F., & Chen, X. (2018) · BMC Cancer · doi:10.1186/s12885-018-4870-z · Cited by 26
Charawi, S., Just, P., Savall, M., Abitbol, S., Traoré, M., Metzger, N., Ravinger, R., Cavard, C., Terris, B., & Perret, C. (2018) · The Journal of Pathology · doi:10.1002/path.5202 · Cited by 26
Gao, M., Huang, A., Sun, Z., Sun, Y. H., Chang, B., Zhang, J., & Zou, Z. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14109 · Cited by 26
Self-citationLi, J., Xu, J., & Li, Z. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101116 · Cited by 26
Keam, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02002-x · Cited by 26
Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma
Jeng, K., Jeng, C., Jeng, W., Sheen, I., Chang, C., Hsiau, H.-I., Hung, Z.-H., Yu, M.-C., & Chang, F. (2015) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2015.03.001 · Cited by 25
Zhao, S., Wu, W., Jiang, H., Ma, L., Pan, C., Jin, C., Mo, J., Wang, L., & Wang, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.731527 · Cited by 25
Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y. W., Liu, H., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03593-3 · Cited by 25
Self-citationXu, J., Zhang, L., Li, N., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215970 · Cited by 25
Huo, R., Chen, Y., Li, J., Xu, Q.-G., Guo, J., Xu, H., You, Y., Zheng, C., & Chen, Y. (2023) · Current Oncology · doi:10.3390/curroncol30020141 · Cited by 25
Qian, Y., Li, Y., Zheng, C., Lu, T., Sun, R., Mao, Y., Yu, S., Fan, H., & Zhang, Z. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.04.077 · Cited by 24
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
Digiacomo, G., Fumarola, C., Monica, S. L., Bonelli, M. A., Cavazzoni, A., Galetti, M., Terenziani, R., Eltayeb, K., Volta, F., Zoppi, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942341 · Cited by 24
Fujita, M., Chen, M.-J. M., Siwak, D. R., Sasagawa, S., Oosawa-Tatsuguchi, A., Arihiro, K., Ono, A., Miura, R., Maejima, K., Aikata, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34249-x · Cited by 24
Choo, S. P., Chowbay, B., Ng, Q. S., Thng, C. H., Lim, C., Hartono, S., Koh, T. S., Huynh, H. T., Poon, D., Ang, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.008 · Cited by 23
Haluska, P., Shaw, H. M., Batzel, G. N., Molife, L. R., Adjei, A. A., Yap, T. A., Roberts, M. L., Gualberto, A., & Bono, J. S. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3586 · Cited by 23
Liu, J., Li, G., Wang, X., Wang, L., Zhao, R., Wang, J., Kong, Y., Ding, J., Li, J., & Zhang, L. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.01.004 · Cited by 22
Torimura, T., Iwamoto, H., Nakamura, T., Abe, M., Ikezono, Y., Wada, F., Sakaue, T., Masuda, H., Hashimoto, O., Koga, H., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.05.001 · Cited by 22
Murali, M., Kumar, A. R., Nair, B., Pavithran, K., Devan, A. R., Pradeep, G., & Nath, L. R. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02707-5 · Cited by 22
Michalski, M., Bauer, M., Walz, F., Tümen, D., Heumann, P., Stöckert, P., Gunckel, M., Kunst, C., Kandulski, A., Schmid, S. A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061666 · Cited by 22
Tan, Y., Zheng, T., Su, Z., Chen, M., Chen, S., Zhang, R., Wang, R., Li, K., & Na, N. (2023) · JCI Insight · doi:10.1172/jci.insight.162893 · Cited by 22
Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges
Chen, X., Huang, Y., Chen, B., Liu, H., Cai, Y., & Yang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115947 · Cited by 22
Wang, H., Liao, P., Zeng, S. X., & Lu, H. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1685289 · Cited by 21
Liu, J., Liu, Y., Zhang, J., Liu, D., Bao, Y., Chen, T., Tang, T., Lin, J., Luo, Y., Jin, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03108-2 · Cited by 21
Zhao, Z., Xiong, S., Wang, R., Li, Y., Wang, X., Wang, Y., Bai, S., Chen, W., Zhao, Y., & Cheng, B. (2019) · Cancer Management and Research · doi:10.2147/cmar.s192263 · Cited by 20
Nazzal, M., Sur, S., Steele, R., Khatun, M., Patra, T., Phillips, N. J., Long, J., Ray, R., & Ray, R. B. (2020) · Hepatology · doi:10.1002/hep.31298 · Cited by 20
Metadata
- Authors
- Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-02-07
- Volume
- 10
- Issue
- 1
- Pages
- 35-35
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4407203105
- Cited by
- 341
- References
- 641
- FWCI
- 165.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.